Publication: LBA10 Bemarituzumab (BEMA) plus chemotherapy for advanced or metastatic FGFR2b-overexpressing gastric or gastroesophageal junction cancer (G/GEJC): FORTITUDE-101 phase III study results
Loading...
Institution Authors
Author
S.Y. Rha
R.A. Pazo Cid
A. Fernandez Montes
S. Qin
S.J. Klempner
A. Elme
H.M. Türk
C. Pozzo
A. Ranceva
J. Li
Advisor
Program
Date
Language
Type
Publisher
Elsevier BV
Journal Title
Journal ISSN
Volume Title
Abstract
Description
Source
OpenAire